Urethritis and antimicrobial resistance

1. Centers for Disease Control and Prevention. Sexually transmitted diseases surveillance c 2008 [updated 2009 Nov 16; cited 2012 Nov 25]. Available from: http:/www.cdc.gov/std/stats08/tables/2.htmSearch in Google Scholar

2. Miller WC, Ford CA, Morris M, Handcock MS, Schmitz JL, Hobbs MM, et al. Prevalance of chlamydial and gonococcal infections among young adults in the United States. JAMA 2004;291(18):2229-36.10.1001/jama.291.18.2229Search in Google Scholar

3. Shahmanesh M, Moi H, Lassau F, Janier M. European guideline on the management of male non-gonococcal urethritis. Int J STD AIDS 2009;20:458-64.10.1258/ijsa.2009.009143Search in Google Scholar

4. Bradshaw CS, Tabrizi SN, Fairley CK, Morton AN, Rudland E, Garland SM. The association of Atopobium vaginae and Gardnerella vaginalis with bacterial vaginosis and recurrence after oral metronidazole therapy. J Infect Dis 2006;194(6):828-36.10.1086/506621Search in Google Scholar

5. Morton RS. Gonorrhea: biological features of Neisseria gonorrhoeae. London: W.B. Saunders; 1977. p. 12-60.Search in Google Scholar

6. Mahoney JF, Ferguson C, Buchholtz M, von Slyke CJ. The use of penicillin sodium in the treatment of sulfonamide-resistant gonorrhea in men: a preliminary report. Am J Syph Gonor Vener Dis 1943;27:525-8.Search in Google Scholar

7. Willcox RR. A survey of problems in the antibiotic treatment of gonorrhoea: with special reference to South-East Asia. Br J Vener Dis 1970;46:217-42.10.1136/sti.46.3.217Search in Google Scholar

8. Philips I. Beta-lactamase producing, penicillin-resistant gonococcus. Lancet 1976;2:656-7.10.1016/S0140-6736(76)92466-1Search in Google Scholar

9. Schwarcz SK, Zenilman JM, Schnell D, Knapp JS, Hook EW 3rd, Thompson S, et al. National surveillance of antimicrobial resistance in Neisseria gonorrhoeae: the gonococcal isolate surveillance project. JAMA 1990;264:1413-7.10.1001/jama.1990.03450110059027Search in Google Scholar

10. Tapsall JW, Ndowa F, Lewis DA, Unemo M. Meeting the public health challenge of multidrug and extensively drug resistant Neisseria gonorrhoeae. Expert Rev Anti Infect Ther 2009;7:821-34.10.1586/eri.09.6319735224Search in Google Scholar

11. Tapsall JW. Antibiotic resistance in Neisseria gonorrhoeae. Clin Infect Dis 2005;41 (Suppl 4):S263-8.10.1086/43078716032562Search in Google Scholar

12. Centers for Disease Control and Prevention (CDC). Update to CDC’s sexually transmitted diseases treatment guidelines, 2006: fluoroquinolones no longer recommended for treatment of gonococcal infections. MMWR Morb Mortal Wkly Rep 2007;56:332-6.Search in Google Scholar

13. Bignell C, Garley J. Azithromycin in the treatment of infection with Neisseria gonorrhoeae. Sex Transm Infect 2010;86:422-6.10.1136/sti.2010.04458620940153Search in Google Scholar

14. Chisholm SA, Neal TJ, Alawattegama AB. Emergence of high-level azithromycin resistance in Neisseria gonorrhoea in England and Wales. J Antimicrob Chemother 2009;64:353-8.10.1093/jac/dkp18819468025Search in Google Scholar

15. Moran JS, Levine WC. Drugs of choice for the treatment of uncomplicated gonococcal infections. Clin Infect Dis 1995;20(Suppl 1):S47-65.10.1093/clinids/20.Supplement_1.S47Search in Google Scholar

16. Newman LM, Moran JS, Workowski KA. Update on the management of gonorrhea in adults in the United States. Clin Infect Dis 2007;44(Suppl 3):S84-101.10.1086/51142217342672Search in Google Scholar

17. Akasaka S, Muratani T, Yamada Y, Inatomi H, Takahachi K, Matsumoto T. Emergence of cephem- and aztreonam-highresistant Neisseria gonorrhoeae that does not produce betalactamase. J Infect Chemother 2001;7(1):49-50.10.1007/s10156017003411406757Search in Google Scholar

18. Unemo M, Golparian D, Syversen G, Vestrheim DF, Moi H. Two cases of verified clinical failures using internationally recommended first-line cefixime for gonorrhoea treatment, Norway, 2010. Euro Surveill 2010;15(47).10.2807/ese.15.47.19721-en21144442Search in Google Scholar

19. Ohnishi M, Golparian D, Shimuta K, Saika T, Hoshina S, Iwasaku K, et al. Is Neisseria gonorrhoeae initiating a future era of untreatable gonorrhea?: detailed characterization of the first strain with high-level resistance to ceftriaxone. Antimicrob Agents Chemother 2011;55(7):3538-45.10.1128/AAC.00325-11312241621576437Search in Google Scholar

20. Unemo M, Golparian D, Nicholas R, Ohnishi M, Gallay A, Sednaoui P. High-level cefixime- and ceftriaxone-resistant Neisseria gonorrhoeae in France: novel penA mosaic allele in a successful international clone causes treatment failure. Antimicrob Agents Chemother 2012;56(3):1273-80.10.1128/AAC.05760-11329489222155830Search in Google Scholar

21. Lewis DA. The Gonococcus fights back: is this time a knock out? Sex Transm Infect 2010;86:415-21.Search in Google Scholar

22. Bignell C, Fitzgerald M. UK national guideline for the management of gonorrhoea in adults, 2011. Int J STD AIDS 2011;22:541-7.10.1258/ijsa.2011.01126721998172Search in Google Scholar

23. Ison CA. Antimicrobial resistance in sexually transmitted infections in the developed world: implications for rational treatment. Curr Opin Infect Dis 2012;25:73-8.10.1097/QCO.0b013e32834e9a6a22143116Search in Google Scholar

24. Bignell C, Unemo M. 2012 European guideline on the diagnosis and treatment of gonorrhoea in adults, IUSTI 2012. [cited 2012 Nov 25]. Available from: http://www.iusti.org/regions/Europe/pdf/2012/Gonorrhoea_2012.pdf.Search in Google Scholar

25. PHAC. Important notice. Public health information update on the treatment for gonococcal infection. 21 December 2011. [cited 2012 Nov 25]. Available from: http://www.phac-aspc.gc.ca/std-mts/sti-its/alert/2011/alert-gono-eng.phpSearch in Google Scholar

26. Ross JD, Lewis DA. Cephalosporin resistant Neisseria gonorrhoeae: time to consider gentamicin? Sex Transm Infect 2012; 88(1):6-8.Search in Google Scholar

27. Golparian D, Fernandes P, Ohnishi M, Jensen JS, Unemo M. In vitro activity of the new fluoroketolide solithromycin (CEM-101) against a large collection of clinical Neisseria gonorrhoeae isolates and international reference strains, including those with various high-level antimicrobial resistance: potential treatment option for gonorrhea? Antimicrob Agents Chemother 2012;56(5):2739-42.Search in Google Scholar

28. Still JG, Schranz J, Degenhardt TP, Scott D, Fernandes P, Gutierrez MJ, et al. Pharmacokinetics of solithromycin (CEM-101) after single or multiple oral doses and effects of food on single-dose bioavailability in healthy adult subjects. Antimicrob Agents Chemother 2011;55(5):1997-2003.10.1128/AAC.01429-10308820521282444Search in Google Scholar

29. Unemo M, Golparian D, Limnios A, Whiley D, Ohnishi M, Lahra MM, et al. In vitro activity of ertapenem versus ceftriaxone against Neisseria gonorrhoeae isolates with highly diverse ceftriaxone MIC values and effects of ceftriaxone resistance determinants: ertapenem for treatment of gonorrhea? Antimicrob Agents Chemother 2012;56(7):3603-9.Search in Google Scholar

30. Andersen B, Sokolowski I, Ostergaard L, Moller JK, Olesen F, Jensen JS. Mycoplasma genitalium: prevalence and behavioural risk factors in the general population. Sex Transm Infect 2007;83:237-41.10.1136/sti.2006.022970265910417090566Search in Google Scholar

31. Totten PA, Schwartz MA, Sjostrom KE, Kenny GE, Handsfield HH, Weiss JB, et al. Association of Mycoplasma genitalium with nongonococcal urethritis in heterosexual men. J Infect Dis 2001;183:269-76.10.1086/31794211120932Search in Google Scholar

32. Cazanave C, Manhart LE, Bebear C. Mycoplasma genitalium, an emerging sexually transmitted pathogen. Med Mal Infect 2012;42:381-92.10.1016/j.medmal.2012.05.00622975074Search in Google Scholar

33. Humasuna R, Osada Y, Jensen JS. Antibiotic susceptibility testing of Mycoplasma genitalium by TaqMan 5’nuclease realtime PCR. Antimicrob Agents Chemother 2005;49:4993-8.10.1128/AAC.49.12.4993-4998.2005131594616304163Search in Google Scholar

34. Shimada Y, Deguchi T, Nakane K, Yasuda M, Yokai S, Ito S, et al. Macrolide resistance-associated 23S rRNA mutation in Mycoplasma genitalium, Japan. Emerg Infect Dis 2011;17(6):1148-50.10.3201/eid1706.101055Search in Google Scholar

35. Bjornelius E, Anagrius C, Bojs G, Carlberg H, Johannisson G, Johansson E, et al. Antibiotic treatment of symptomatic Mycoplasma genitalium infection in Scandinavia: a controlled clinical trial. Sex Transm Infect 2008;84(1):72-6.10.1136/sti.2007.02737517932127Search in Google Scholar

36. Schwebke JR, Rompalo A, Taylor S, Sena AC, Martin DH, Lopez LM, et al. Re-evaluating the treatment of nongonococcal urethritis: emphasizing emerging pathogens: a randomized clinical trial. Clin Infect Dis 2011;52(2):163-70.10.1093/cid/ciq074310625221288838Search in Google Scholar

37. Wikstrom A, Jensen JS. Mycoplasma genitalium: a common cause of persistent urethritis among men treated with doxycycline. Sex Trasm Infect 2006;82(4):276-9.10.1136/sti.2005.018598256470716877573Search in Google Scholar

38. Ray WA, Murray KT, Hall K, Arbogast PG, Stein CM. Azithromycin and the risk of cardiovascular death. N Engl J Med 2012;366:1881-90.10.1056/NEJMoa1003833337485722591294Search in Google Scholar

39. Jernberg E, Moghaddam A, Moi H. Azithromycin and moxifloxacin for microbiological cure of Mycoplasma genitalium infection: an open study. Int J STD AIDS 2008;19(10):676-9.10.1258/ijsa.2008.00803818824619Search in Google Scholar

40. Manhart LE, Broad JM, Golden MR. Mycoplasma genitalium: should we treat and how? Clin Infect Dis 2011;53(Suppl 3):S129-42.10.1093/cid/cir702321340222080266Search in Google Scholar

41. Horner P, Thomas B, Gilroy CB, Egger M, Taylor-Robinson D. Role of Mycoplasma genitalium and Ureaplasma urealyticum in acute and chronic nongonococcal urethritis. Clin Infect Dis 2001;32:995-1003.10.1086/31959411264026Search in Google Scholar

42. Kenny GE. Genital mycoplasmas: Mycoplasma genitalium, Mycoplasma hominis et Ureaplasma species. In: Mandel GL, Bennett JE, Dolin R. Principles and practice of infectious diseases. Vol 2. Philadelphia, Pa: Elsevier Churchill Livingstone; 2005. p. 2280-3.Search in Google Scholar

43. Uuskula A. Kohl PK. Genital micoplasmas, including Mycoplasma genitalium, as sexually transmitted agents. Int J STD AIDS 2002;13:79-85.10.1258/095646202192469511839161Search in Google Scholar

44. Taylor-Robinson D, Furr PM, Webster AD. Ureaplasma urealyticum causing persistent urethritis in a patient with hypogammaglobulinaemia. Genitourin Med 1985;61:404-8.10.1136/sti.61.6.40410118704086030Search in Google Scholar

45. Palu G, Valisena S, Barile MF, Meloni GA. Mechanisms of macrolide resistance in Ureaplasma urealyticum: a study on collection and clinical strains. Eur J Epidemiol 1989;5:146-53.10.1007/BF001568202767221Search in Google Scholar

46. Pereyre S, Metifiot M, Cazanave C, Renaudin H, Charron A, Bebear C, et al. Characterisation of in vitro-selected mutants of Ureaplasma parvum resistant to macrolides and related antibiotics. Int J Antimicorb Agents 2007;29:207-11.10.1016/j.ijantimicag.2006.09.00817196370Search in Google Scholar

47. Waites KB, Bebear CM, Roberston JA, Talkington DF, Kenny GE. Cumitech 34: laboratory diagnosis of mycoplasmal infections. Washington DC: American Society for Microbiology; 2001.Search in Google Scholar

48. Lu C, Ye TL, Zhu GX, Feng PY, Ma H, Lu RB, et al. Phenotypic and genetic characteristics of macrolide and lincosamide-resistant Ureaplasma urealyticum isolated in Guangzhou, China. Curr Microbiol 2010;61:44-9.10.1007/s00284-009-9574-920043167Search in Google Scholar

49. Centers for Disease Control and Prevention: Sexually transmitted diseases treatment guidelines. MMWR 2010:42 [cited 2012 Nov 25]. Available from: http://www.cdc.gov/mmwr/pdf/rr/rr5912.pdf.Search in Google Scholar

50. Horner P, Boag F. UK national guideline for the management of genital tract infection with Chlamydia trachomatis. London: BASHH, 2006. [cited 2012 Nov 25]. Available from: hpp://www.bashh.org/documents/61/61.pdf.Search in Google Scholar

51. Lanjouw, Ossewaarde JM, Stary A, Boag F. European guideline for the management of Chlamydia trachomatis infections, IUSTI 2010. [cited 2012 Nov 25]. Available from: http://www.iusti.org/regions/Europe/pdf/2010/Euro_Guideline_ Chlamydia_2010.pdf.10.1258/ijsa.2010.01030221187352Search in Google Scholar

52. Horner PJ. Azithromycin antimicrobial resistance and genital Chlamidya trachomatis infection: duration of therapy may the key to improving efficacy. Sex Transm Infect 2012;88:154-6.10.1136/sextrans-2011-05038522416272Search in Google Scholar

53. Wang SA, Papp JR, Stamm WE, Peeling RW, Martin DH, Holmes KK. Evaluation of antimicrobial resistance and treatment failures for Chlamydia trachomatis: a meeting report. J Infect Dis 2005;191:917-23.10.1086/42829015717267Search in Google Scholar

54. Smelov V, Perekalina T, Gorelov A, Smelova N, Artemenko N, Norman L. In vitro activity of fluoroquinolones, azithromycin and doxocycline against Chlamydia trachomatis cultured from men with chronic lower urinary tract symptoms. Eur Urol 2004;46(5):647-50.10.1016/j.eururo.2004.06.02015474277Search in Google Scholar